Heart Disease Clinical Trials in Seattle

Showing 81-100 of 245 trials

Repurposing Valsartan May Protect Against Pulmonary Hypertension

NCT06053580

This is a Phase 2, single-center, randomized placebo controlled trial of valsartan (an angiotensin receptor blocker) in adults with pulmonary arterial hypertension. The study will evaluate the safety and clinical efficacy of a 24-week course of valsartan.

Pulmonary Arterial HypertensionRight Heart FailureRight Ventricular Dysfunction+1 more

University of Washington60 participantsStarted Feb 2024

Seattle, Washington, United States

COMPLETEDPhase 3< 1 mile

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

NCT03988634

The effect of sacubitril/valsartan vs. valsartan on changes in NT-proBNP, safety, and tolerability in HFpEF patients with a WHF event (HFpEF decompensation) who had been stabilized and initiated at the time of or within 30 days post-decompensation.

Heart Failure With Preserved Ejection Fraction (HFpEF)

Novartis Pharmaceuticals467 participantsStarted Jun 2019

Irvine, California, United States • Long Beach, California, United States • Los Angeles, California, United States +94 more locations

Repurposing Valsartan May Protect Against Pulmonary Hypertension

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

Heart Disease Trials in Other Cities

PROACTIVE-HF IDE Trial Heart Failure NYHA Class III

The CorCinch - Functional Mitral Valve Regurgitation (FMR) Study

Impact of Patient-Centered Approach for Communicating Coronary Calcium on Cardiovascular Health

Multicenter Automatic Defibrillator Implantation Trial With Subcutaneous Implantable Cardioverter Defibrillator

Advancing Symptom Alleviation With Palliative Treatment

ILUMIEN IV: OPTIMAL Percutaneous Coronary Intervention (PCI)

Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

Physiologic Pacing Registry

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Benefits of Microcor in Ambulatory Decompensated Heart Failure

Randomized Ablation-based AF Rhythm-control Versus Rate-control in Patients With HF and High-burden AF Extend

Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia

Distal Evaluation of Functional Performance with Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting

Multidisciplinary Approach for High-risk Patients Leading to Early Diagnosis of Canadians With Heart Failure

Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates

Multiple Cardiac Sensors for the Management of Heart Failure

Effect of Fetal Aortic Valvuloplasty on Outcomes

Other Conditions in Seattle